DDInter1506 DDInter1763
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etacrynic acid
Etacrynic acid {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) CDK19
CDK19 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Grepafloxacin
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conjugated estrogens
Conjugated estrogens {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) downregulates {v} (Gene) DKK3
DKK3 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofloxacin
Ofloxacin {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etacrynic acid
Etacrynic acid {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates SMARCD2 (Gene) and SMARCD2 (Gene) is downregulated by Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is upregulated by Temsirolimus (Compound)
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) downregulates DKK3 (Gene) and DKK3 (Gene) is upregulated by Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is downregulated by Temsirolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Temsirolimus (Compound)